Course Description
Infiltrative Cardiomyopathy Symposium–
Infiltrative cardiomyopathies, including cardiac amyloidosis and cardiac sarcoidosis, are complex and often underdiagnosed conditions that require early recognition, specialized evaluation, and coordinated, multidisciplinary care. This educational course is designed to address key knowledge gaps among clinicians by providing up-to-date information on diagnostic strategies, pharmacologic therapies, and advanced treatment options, including ICD and pacemaker implantation, LVAD therapy, and heart transplantation. Participants will gain a deeper understanding of how to identify and manage these conditions using a patient-centered and team-based approach.
Through expert-led lectures, real-world case discussions, interactive Q&A sessions, and a keynote address from a recognized leader in the field, this course will offer practical, clinically relevant tools to enhance decision-making and improve outcomes. Attendees will be better equipped to recognize the signs of infiltrative heart disease, utilize advanced imaging and referral pathways, and implement comprehensive treatment plans in collaboration with subspecialists across cardiology, electrophysiology, imaging, and heart failure care.
Target Audience
- Cardiology healthcare professionals and fellows involved in heart failure management
- Nurse practitioners, physician assistants, and allied health professionals
- Specialists in electrophysiology, interventional, imaging, and advanced heart failure cardiology
- Specialists in pulmonary, rheumatology, neurology, radiology, pathology.
- Primary care providers and general cardiologists
Learning Objectives
Upon completion of this activity, learners will be able to:
- Recognize unique conditions in patients with heart disease, including cardiac amyloidosis and cardiac sarcoidosis.
- Identify the appropriate timing for specialized diagnostics and referral to specialists.
- Describe the evaluation process for suspected infiltrative cardiomyopathy.
- Explore the most current treatment modalities for infiltrative cardiomyopathies, including pharmacologic options, advanced heart failure therapies, and interventional therapies.
- Review the selection criteria for ICD and pacemaker implantation.
This course is officially endorsed by the Heart Failure Society of America.
For more information on HFSA Endorsed Programs, visit www.hfsa.org.
The opinions presented in this educational activity do not necessarily reflect the opinions or recommendations of the HFSA.
Early Bird Registration
June 1 - October 31, 2026
Physician
$100
Allied Health
$60
IN-TRAINING
Complimentary*
Industry
$300
Full Registration
November 1 - December 5, 2026
Physician
$200
Allied Health
$125
IN-TRAINING
Complimentary*
Industry
$325
Registration for Infiltrative Cardiomyopathy Symposium
*If you are a fellow or resident in-training, please email a letter of good standing from your program director to info@infiltrativecardio.org for a complimentary registration code.
To register, click the corresponding registration type button to visit our secure registration platform. We are unable to accept registrations or cancellations by telephone. Please submit all inquiries via email to info@infiltrativecardio.org.
Cancellation Policy
Cancellations made in writing by October 31, 2025, will be subject to a 50% penalty. No refunds will be given starting November 1, 2025. Cancellations will not be accepted by telephone. In the unlikely event that the course is cancelled, we will refund the registration fee, but are not responsible for any travel costs.
Please contact us at info@infiltrativecardio.org if you have questions or need additional information.
FEATURED KEYNOTE SESSION
Criteria, Consortia and Clinical Trials:
The Evolving Field of Cardiac Sarcoidosis
Presented By: Jordana Kron, MD
Virginia Commonwealth University
Event Schedule
NOTE: This is a draft agenda and subject to change
Morning Session
Saturday, December 5, 2026
7:15 AM
Registration and Breakfast
Breakfast Presentation - Sponsored by Alnylam
Speaker:
Room: Chesapeake B
Session I | Identifying and Diagnosing Infiltrative Cardiomyopathies
Room: Chesapeake C
8:15 AM
Welcome and Introduction
Nisha A. Gilotra, MD, and Farooq H. Sheikh, MD
8:20 AM
Lay of the Land: When to Suspect Infiltrative Heart Diseases
8:35 AM
Clinical Manifestations and Diagnostic Algorithm: Cardiac Amyloidosis
8:50 AM
Evaluation of Systemic Sarcoidosis
Kristen Mathias, MD
9:05 AM
Panel Discussion
Moderator: Tania Vora, MD
Panelist: Kristen Mathias, MD
Keynote Speaker
Room: Chesapeake C
9:20 AM
Criteria, Consortia and Clinical Trials: The Evolving Field of Cardiac Sarcoidosis
Keynote Speaker: Jordana Kron, MD
Moderator: Nisha A. Gilotra, MD, and Farooq H. Sheikh, MD
Break
10:20 AM
Refreshments and Exhibits
Session II | Diagnostic Tools in Infiltrative Cardiomyopathy
Room: Chesapeake C
11:05 AM
The Role of Echocardiography
Allison G. Hays, MD
11:15 AM
Cardiac MRI in Infiltrative Cardiomyopathies
Claire Brookmeyer, MD
11:25 AM
Cardiac Scintigraphy in Cardiac Amyloidosis
11:35 AM
FDG PET Imaging in Inflammatory Cardiomyopathies
Paco E. Bravo, MD
11:45 AM
Hemos and Histo: The Role of Right Heart Catheterization and Endomyocardial Biopsy
Mitchell Psotka, MD, PhD
11:55 AM
Incorporation of Genetic Testing in the Diagnostic Evaluation
Brittney Murray, MS, CGC
12:05 PM
Panel Discussion
Panelists: Paco E. Bravo, MD; Claire Brookmeyer, MD; Allison G. Hays, MD; Brittney Murray, MS, CGC; and Mitchell Psotka, MD, PhD
Afternoon Session
Saturday, December 5, 2026
12:20 PM
Lunch
Lunch Presentation - Sponsored by BridgeBio
Speaker: Jan Griffin, MD
Room: Chesapeake B
Break | Dessert and Networking
Session III | Therapeutic Landscape for Infiltrative Cardiomyopathies
Room: Chesapeake C
1:35 PM
How to Apply the Heart Failure Guidelines in Treating Infiltrative Cardiomyopathies
Paul J. Scheel III, MD
1:50 PM
Taming the Heart: Immunosuppression for Cardiac Sarcoidosis
Nisha A. Gilotra, MD
2:05 PM
Treating the Tangles: Cardiac Amyloidosis
Sumeet Mitter, MD, MSc
2:20 PM
Pharmacotherapy Potpourri from a Pharmacist's Perspective
Sara Strout, PharmD
2:35 PM
Electrophysiology Considerations in Infiltrative Cardiomyopathies
Jonathan Chrispin, MD
2:50 PM
Heart Transplantation and LVAD Therapy
Joban Vaishnav, MD
3:05 PM
Panel Discussion
Moderator: Jana P. Lovell MD
Panelists: Jonathan Chrispin, MD; Nisha A. Gilotra, MD; Sumeet Mitter, MD, MSc; Paul J. Scheel III, MD; Sara Strout, PharmD; and Joban Vaishnav, MD
Session IV | Cardiomyopathy Conundrums: Case-Based Conversation
Room: Chesapeake C
3:20 PM
Case Presentation 1
Anjali Wagle, MD
3:30 PM
Panel Discussion and Q&A
Moderators: Sumeet Mitter, MD, MSc and Joban Vaishnav, MD
3:45 PM
Case Presentation 2
3:55 PM
Panel Discussion and Q&A
Moderators: Sumeet Mitter, MD, MSc and Joban Vaishnav, MD
4:15 PM
Closing Remarks
Nisha A. Gilotra, MD, and Farooq H. Sheikh, MD
4:20 PM
Adjourn
Faculty
Course Directors
Nisha A. Gilotra, MD
Johns Hopkins Medicine
Baltimore, MD
Farooq H. Sheikh, MD
MedStar Health
Washington, DC
Planning Committee
Albert J. Hicks III, MD, MPH
University of Maryland
Baltimore, MD
Gurusher Panjrath, MD
George Washington University
Washington, DC
Joban Vaishnav, MD
Johns Hopkins Medicine
Baltimore, MD
Sumeet S. Mitter, MD, MSc
Inova
Falls Church, VA
Mitchell Psotka MD, PhD
Inova
Falls Church, VA
Nana Afari-Armah, MD
MedStar Health
Washington, DC
Claire Brookmeyer, MD
Johns Hopkins Medicine
Balitmore, MD
Paco E. Bravo, MD
University of Pennsylvania
Philadelphia, PA
Jonathan Chrispin, MD
Johns Hopkins Medicine
Baltimore, MD
Allison G. Hays, MD
Johns Hopkins Medicine
Baltimore, MD
Albert J. Hicks III, MD, MPH
University of Maryland
Baltimore, MD
Sandeep M. Jani, MD
MedStar Health
Washington, DC
Ajay Kadakkal, MD
MedStar Health
Washington, DC
Jordana Kron, MD
VCU Health
Richmond, VA
Jana P. Lovell, MD
Johns Hopkins Medicine
Baltimore, MD
Kristen Mathias, MD
Johns Hopkins Medicine
Baltimore, MD
Sumeet S. Mitter, MD, MSc
Inova
Falls Church, VA
Brittney Murray, MS, CGC
Johns Hopkins Medicine
Baltimore, MD
Gurusher Panjrath, MD
George Washington University
Washington, DC
Mitchell Psotka MD, PhD
Inova
Falls Church, VA
Sara Strout, PharmD
Johns Hopkins Medicine
Baltimore, MD
Paul J. Scheel III, MD
Johns Hopkins Medicine
Baltimore, MD
Joban Vaishnav, MD
Johns Hopkins Medicine
Balitmore, MD
Tania A. Vora, MD
MedStar Health
Washington, DC
Anjali Wagle, MD
Johns Hopkins Medicine
Baltimore, MD
Zackary J. Tushak, DO
Sentara
Norfolk, VA
CME Accreditation
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.
Disclaimer
Guidelines require that learners in CME activities be made aware of all relevant financial relationships affecting the presentation of the faculty member. ACHL ensures that all faculty and staff involved in the planning, development, and implementation of ACHL activities disclose financial relationships held within 24 months and that relevant financial relationships are mitigated before a CME activity occurs. Complete information will be provided to learners prior to the start of the educational activity.
Exhibitors
Infiltrative Cardiomyopathy Symposium is a one-day program designed to provide a venue for attendees to review infiltrative heart diseases, such as cardiac amyloidosis and cardiac sarcoidosis, pose unique diagnostic and therapeutic challenges. Due to their rarity and complexity, healthcare providers may lack familiarity with optimal strategies for early recognition, specialized evaluation, and multidisciplinary care. These conditions require timely referral and coordinated treatment approaches, including advanced pharmacologic therapies, multi-organ management, cardiac surgical interventions like LVAD implantation and heart transplantation, as well as appropriate use of implantable cardioverter defibrillators (ICDs) and pacemakers.
